Diabetes management is not a single A1c target applied to every patient. The right glycemic goal, medication class, and treatment intensity depend on who the patient is — their comorbidities, hypoglycemia risk, kidney function, weight goals, cost and access, and life expectancy.
CLINICAL PRINTABLE
Coming Soon.
A one-page Diabetes Management — Beyond the A1c clinical reference is on the way.
1 · Recognition / First-Pass Assessment
- Clarify diabetes type, duration, current regimen, adherence/access, glucose pattern, hypoglycemia history, complications, kidney function, cardiovascular/HF history, weight trajectory, and patient priorities.
- Use A1c with SMBG/CGM or serum glucose context when discordance is possible; A1c is an average, not a description of excursions.
- Screen for urgent hyperglycemic illness when symptoms, ketones, dehydration, altered mentation, vomiting, or marked metabolic abnormalities are present.
- Distinguish Type 1 from Type 2 — insulin dependence, DKA history, age of onset, C-peptide, and antibody status inform the distinction when it is unclear.
2 · Treatment Pathway
Lifestyle and self-management
Lifestyle and diabetes self-management support remain foundational but should not be used to delay indicated pharmacotherapy.
Metformin
Metformin remains a common foundational agent when appropriate, with renal function and tolerance guiding use. Hold for contrast procedures and acute illness per institutional protocol.
GLP-1 / dual incretin strategies
GLP-1 receptor agonist / dual incretin strategies can be useful when weight reduction and/or cardiovascular risk reduction are priorities in appropriate patients; GI tolerance, gallbladder/pancreatic considerations, access, and contraindications matter.
SGLT2 inhibitors
SGLT2 inhibitors have important heart-failure and kidney benefits in appropriate patients, sometimes independent of glucose lowering; counsel on volume status, genital infections, sick-day/peri-procedure risk, and euglycemic ketoacidosis.
Sulfonylureas and insulin
Sulfonylureas and insulin can lower glucose effectively but carry greater hypoglycemia risk; treatment intensity should fit the patient's ability to monitor and safely respond.
DPP-4 inhibitors, TZDs, and other classes
DPP-4 inhibitors, TZDs, and other classes have distinct efficacy, organ-function, HF, adverse-effect, and cost considerations.
3 · Intensify vs De-intensify
- Intensify when the individualized goal is not met after confirming adherence, access, regimen fit, and reversible contributors.
- De-intensify when hypoglycemia risk is high, life expectancy is limited, functional status has declined, or the patient's goals have shifted — overtreating frail elderly patients causes real harm.
- Individualize the A1c target: tighter control in younger patients with long life expectancy and low hypoglycemia risk; less aggressive targets in older patients, those with hypoglycemia unawareness, or limited life expectancy.
4 · Expected Response / Monitoring
- A1c reflects average glucose over approximately 3 months; expect meaningful change at 3-month follow-up after a regimen change.
- Fasting glucose and postprandial glucose respond faster than A1c — use SMBG or CGM data to assess early response.
- Weight, blood pressure, lipids, kidney function, and urine albumin are co-management targets — not just glucose.
- Failure to respond after confirming adherence and access should prompt regimen reassessment, not just dose escalation.
5 · Escalation
- DKA or HHS: IV insulin, aggressive fluid resuscitation, electrolyte replacement, and hospital-level monitoring.
- Severe hypoglycemia with altered consciousness: IV dextrose or glucagon; evaluate and address the cause before discharge.
- Rapidly progressive kidney disease, new cardiovascular events, or significant weight loss warrant urgent evaluation and specialist input.
- Endocrinology referral for Type 1 diabetes, complex insulin regimens, recurrent DKA, or management that is not responding to standard approaches.
Apply It · Change One Detail
APPLY IT
A 72-year-old with Type 2 diabetes, CKD stage 3b, and a recent fall has an A1c of 8.9%. The instinct is to intensify. But with hypoglycemia risk from CKD, fall history, and age — the right question is whether the current target is appropriate, not just whether the A1c is high.
CHANGE ONE DETAIL
Change one detail — the same patient is 52 years old with no CKD, no fall history, and an A1c of 8.9% — and intensification with an SGLT2 inhibitor or GLP-1 agonist for cardiovascular and kidney benefit becomes the right move.
Bottom Line
Treat the patient, not just the A1c. The right glycemic target, medication class, and intensity depend on who the patient is — not just what the number says.
EVIDENCE & REFERENCES
- American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1). https://diabetesjournals.org/care/issue/47/Supplement_1
- Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034